posted on 2020-07-10, 15:15authored byJoshua P Smalley, Grace E Adams, Christopher J Millard, Yun Song, James KS Norris, John WR Schwabe, Shaun Michael Cowley, James T Hodgkinson
We have identified a proteolysis targeting chimera (PROTAC) of class I HDACs 1, 2 and 3. The most active degrader consists of a benzamide HDAC inhibitor, an alkyl linker, and the von Hippel-Lindau E3 ligand. Our PROTAC increased histone acetylation levels and compromised colon cancer HCT116 cell viability, establishing a degradation strategy as an alternative to class I HDAC inhibition.
History
Citation
Chem. Commun., 2020,56, 4476-4479
Author affiliation
Leicester Institute of Structural and Chemical Biology and Department of Chemistry